Eisai, based in Japan, is moving into Latin America and is opening a subsidiary in Brazil, according to Pharma Times.

Eisai Brazil will be based in Sao Paulo, the country’s largest city, and will first establish "an initial infrastructure to support its operations debut" into that market. The company will focus on neurology, oncology and critical care.

Hajime Shimizu, president of new markets and the Association of Southeast Asian Nations (ASEAN) for Eisai, said the establishment of the unit "marks our entry into Latin America.” He added that the expansion "will enable us to introduce many of Eisai’s first-in-class products to people living in Brazil."